The FDA Friday granted approval to Shire’s Vyvanse (lisdexamfetamine) as a treatment for attention deficit hyperactivity disorder (ADHD).
Shire hopes the drug, which is harder to abuse than older stimulants, will revitalize the company’s ADHD franchise, once Adderall XR begins facing generic competition in 2009.
Adderall XR brought in approximately $975 million in sales for Shire in 2005, followed by McNeil Consumer and Specialty
Pharmaceuticals’ Concerta with sales of $838 million and Eli Lilly’s Strattera, with sales of $662 million.
Shire developed Vyvanse in conjunction with New River Pharmaceuticals of Radford, VA.
Shire acquired New River in a deal worth $2.6 billion last week.